Signal
Advances in engineered immune cell therapies: in vivo CAR T cells, HIV-targeting CAR-T, and optimized NK cell transduction
Recent studies demonstrate significant progress in engineered immune cell therapies.
rss
clinical_trialsr_and_dsafety_signals
Evidence locked
Today's free sample is only available for the edition's flagship signal.
Evidence preview
- bioRxiv preprints on immune cell engineeringbiorxiv.org
- Efficient NK cell transduction with VSV-G-pseudotyped lentiviral vectorsbioRxiv (all subjects)
- Broadly neutralizing antibody-secreting CAR-T cells elicit Fc-mediated effector functions in vitro and suppress HIV i...bioRxiv (all subjects)